Navigation Links
Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optina™
Date:7/21/2010

GREENWOOD VILLAGE, Colo., July 21 /PRNewswire-FirstCall/ -- Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE) today announced the initiation of a Phase II clinical trial of Optina™ for the treatment of diabetic macular edema, an early stage of diabetic retinopathy. Diabetic macular edema is responsible for most vision loss in patients with diabetes mellitus.

Ampio Pharmaceuticals has completed a formal agreement with St Michael's Hospital, Toronto, Canada as a final step for ethics board approval which is expected in the next few days.  "We are very excited to be commencing this trial and pending the final approval of the ethics board we will commence patient recruitment in the next weeks," stated Don Wingerter, CEO of Ampio Pharmaceuticals. Chief Scientific Officer, Dr. David Bar-Or added, "After accumulating in vitro and animal data, it is gratifying to begin treating patients for this debilitating disease."

Diabetic macular edema and diabetic retinopathy are complications of diabetes mellitus that occur in approximately one third of patients 10 years after the onset of diabetes and are rapidly growing causes of blindness worldwide. There is currently no effective oral medication to treat diabetic macular edema or diabetic retinopathy. Optina™ is a repurposed oral drug with an established human safety profile. Pre-clinical studies have shown the potential for Optina™ to significantly reduce diabetic macular edema in patients.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The product pipeline includes new uses
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. CardioMEMS Completes CHAMPION Clinical Trial Study
2. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
3. Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer
4. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
5. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
6. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
7. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
8. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
9. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
10. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
11. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health ... several new IT value-added reseller (VAR) national contracts that ... goods and services at lower costs. These include manufacturer ... such as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... The ophthalmic therapeutics company Xcovery Vision announced today that ... Ken Mandell, President and COO, will be speaking at ... Annual Meeting in Fort Lauderdale Florida, May 1-5, 2011. ... recounts his repeated success as founder of multiple ...
... Accuracy in radiation therapy demands careful targeting and ... Farber Center for Radiation Oncology , the first and ... is among the first treatment centers to adopt Elekta,s ... patient positioning system that enables clinicians to fine-tune ...
Cached Medicine Technology:Xcovery Vision Founders to Speak at ARVO 2011 2Robotic Couch Provides Extra Degree of Precision for Patients Undergoing Radiation Therapy for Cancer 2
(Date:4/24/2014)... terminology, and the relevance of palliation in advanced ... randomized controlled trials (RCTs). This is the result ... Quality and Efficiency in Health Care (IQWiG), which ... Together with external experts, IQWiG analysed studies on ... malignant melanoma, and pancreatic cancer. For this purpose, ...
(Date:4/24/2014)... awarded one of 30 grants from the National Cancer ... Site in its new National Clinical Trials Network ... of investigators charged with distributing resources in a more ... system reflects recommendations from a 2010 Institute of ... goals:, Faster design, launch, and completion of ...
(Date:4/23/2014)... by Massachusetts General Hospital (MGH) investigators may lead to ... a serious medical problem use of fecal material ... the Clostridium difficile ( C. difficile ) ... the journal Clinical Infectious Diseases , the researchers ... donors unrelated to patients was as successful in curing ...
(Date:4/23/2014)... J. O,Shea, M.D., scientific director at the National Institute ... been named the 2014 recipient of the Ross Prize ... open-access journal Molecular Medicine . The award will ... Academy of Sciences in Manhattan, followed by scientific presentations ... part of the National Institutes of Health. , The ...
(Date:4/23/2014)... researchers have identified an important enzyme pathway that helps ... few chromosomes, a condition that has been directly linked ... professor of biochemistry, found that near the end of ... that ensures any breaks in DNA are fully repaired ... to daughter cells. This process helps safeguard against some ...
Breaking Medicine News(10 mins):Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... of herbal products and medicines has the potential to reach ... the creation of exclusive export promotion zones (EPZ) across ... can be accelerated with the setting up of EPZs in ... rate of over 25 percent in countries like the US, ...
... as marijuana or ganja, can help in the treatment ... body tissues are attacked by its own immune system. ... University of Bonn, used tetrahydrocannabinol (THC), the active ingredient ... that it reduced skin allergies. ,However, the ...
... Today at the 61st Annual Meeting of the ... Cordis Corporation, announced the worldwide launch of the ... use in angioplasty procedures for patients with carotid ... a unique high-pressure expansion and low profile .014 ...
... better way to say "I love you" than showing your Dad ... come . This Father's Day, the American Diabetes Association (ADA) wants ... out by their doctor. ,More than 10 percent of all ... 2 diabetes, the most common form of the disease, can come ...
... number of suicide attempts among asylum seekers in Denmark has ... of despair," according to a study published Thursday . ... camps -- or 0.6 percent of the total -- tried ... by the Danish Association to Help Refugees said. ...
... for a new study has found that regular practice ... as well as the cognitive decline associated with ... practice, is centred on attentional and postural self-regulation and ... normal age-related decline of cerebral gray matter volume and ...
Cached Medicine News:Health News:Export of Herbal Products to Reach Rs.120 Billion by 2012: Study 2Health News:New Balloon Catheter Available Worldwide for Carotid and Renal Angioplasty 2Health News:Drag Dad to the Doctor This Father's Day 2
... Aestiva/5 Pendant anesthesia machine offers proven ... range with the SmartVent ventilator. However, ... superior ventilation. Enhancements in flexibility, ergonomics ... in anesthesia delivery., ,The Aestiva/5 ...
With its integrated design and superior build quality each Prima SP is custom built to meet your requirements....
... Tegagel hydrogel wound filler and ... are amorphous hydrogel dressings specially formulated ... that has been shown to enhance ... formula meets clinical needs for management ...
Features various cylinder sizes and a simple two-handed pumping mechanism....
Medicine Products: